Long-term survival after allogeneic-matched sibling PBSC transplantation with conditioning consisting of low-dose busilvex and fludarabine in a 3-year-old boy with ataxia-telangiectasia syndrome and ALL

Bone Marrow Transplantation

Volumn 48, Issue 5, 2013, Pages 740-741

  Ussowicz, M ^a   Musial J ^a   Duszenko E ^a   Haus, O ^a,b   Kalwak K ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BUSULFAN; CD3 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; CIDOFOVIR; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOSPORIN; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; OKT 3; PREDNISONE; THYMOCYTE ANTIBODY; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AML1 GENE; APHERESIS; ATAXIA TELANGIECTASIA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHILD; CHROMOSOME DELETION; CLINICAL FEATURE; DRUG TREATMENT FAILURE; GENE; GENE DELETION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HYPERLEUKOCYTOSIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KARYOTYPING; LETTER; LEUKOCYTE DISORDER; LONG TERM SURVIVAL; LOW DRUG DOSE; LYMPHOMA; MALE; MUTATIONAL ANALYSIS; PERIPHERAL BLOOD STEM CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; TP53 GENE; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATAXIA TELANGIECTASIA; BUSULFAN; CHILD, PRESCHOOL; HUMANS; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIBLINGS; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 84877657890     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.207     Document Type: Letter

References (8)

1. Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 1986; 39: 573-583.
2. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991; 325: 1831-1836.
3. Seidemann K, Henze G, Beck JD, Sauerbrey A, Kühl J, Mann G et al. Non-Hodgkin's lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials. Ann Oncol 2000; 11(Suppl 1): 141-145.
4. Bienemann K, Burkhardt B, Modlich S, Meyer U, Möricke A, Bienemann K et al. Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey. Br J Haematol 2011; 155: 468-476.
5. Broccoletti T, Del Giudice E, Cirillo E, Vigliano I, Giardino G, Ginocchio VM et al. Efficacy of very-low-dose betamethasone on neurological symptoms in ataxiatelangiectasia. Eur J Neurol 2011; 18: 564-570.
6. EBMT/ESID guidelines for hematopoieic stem cell transplantation for primary immunodeficiencies. 2011, http://www.esid.org/downloads/BMT-Guidelines- 2011.pdf.
7. Ghosh S, Schuster FR, Binder V, Niehues T, Baldus SE, Seiffert P et al. Fatal outcome despite full lympho-hematopoietic reconstitution after allogeneic stem cell transplantation in atypical ataxia telangiectasia. J Clin Immunol 2012; 32: 438-440.
8. Albert MH, Gennery AR, Greil J, Cale CM, Kalwak K, Kondratenko I et al. Successful SCT for Nijmegen breakage syndrome. Bone Marrow Transplant 2010; 45: 622-626.